S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
Log in
NASDAQ:MRKR

Marker Therapeutics Stock Forecast, Price & News

$2.07
-0.06 (-2.82 %)
(As of 01/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.02
Now: $2.07
$2.18
50-Day Range
$1.45
MA: $1.64
$2.13
52-Week Range
$1.32
Now: $2.07
$3.39
Volume640,025 shs
Average Volume887,843 shs
Market Capitalization$99.41 million
P/E RatioN/A
Dividend YieldN/A
Beta1.27
Marker Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA-specific T cell technology is based on the expansion of non-engineered tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, multiple myeloma, and various solid tumors; and allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. It is also developing TPIV100/110, which is in Phase II clinical trial to treat breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

MarketRank

Overall MarketRank

1.14 out of 5 stars

Medical Sector

743rd out of 1,480 stocks

Pharmaceutical Preparations Industry

369th out of 612 stocks

Analyst Opinion: 3.3Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MRKR
CUSIPN/A
CIKN/A
Phone713-400-6400
Employees28

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$210,000.00
Book Value$0.96 per share

Profitability

Net Income$-21,430,000.00

Miscellaneous

Market Cap$99.41 million
Next Earnings Date3/11/2021 (Estimated)
OptionableOptionable
$2.07
-0.06 (-2.82 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MRKR News and Ratings via Email

Sign-up to receive the latest news and ratings for MRKR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Marker Therapeutics (NASDAQ:MRKR) Frequently Asked Questions

How has Marker Therapeutics' stock been impacted by COVID-19?

Marker Therapeutics' stock was trading at $1.98 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MRKR shares have increased by 4.5% and is now trading at $2.07.
View which stocks have been most impacted by COVID-19
.

Is Marker Therapeutics a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Marker Therapeutics in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Marker Therapeutics stock.
View analyst ratings for Marker Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Marker Therapeutics?

Wall Street analysts have given Marker Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Marker Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Marker Therapeutics' next earnings date?

Marker Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Marker Therapeutics
.

How were Marker Therapeutics' earnings last quarter?

Marker Therapeutics, Inc. (NASDAQ:MRKR) issued its earnings results on Monday, November, 9th. The company reported ($0.16) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.15) by $0.01.
View Marker Therapeutics' earnings history
.

What price target have analysts set for MRKR?

5 brokerages have issued 12-month target prices for Marker Therapeutics' shares. Their forecasts range from $2.50 to $16.00. On average, they anticipate Marker Therapeutics' stock price to reach $8.50 in the next year. This suggests a possible upside of 310.6% from the stock's current price.
View analysts' price targets for Marker Therapeutics
or view Wall Street analyst' top-rated stocks.

Who are some of Marker Therapeutics' key competitors?

What other stocks do shareholders of Marker Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Marker Therapeutics investors own include Amarin (AMRN), Viking Therapeutics (VKTX), PhaseBio Pharmaceuticals (PHAS), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Genocea Biosciences (GNCA), Strongbridge Biopharma (SBBP), Flexion Therapeutics (FLXN), Geron (GERN) and Ionis Pharmaceuticals (IONS).

Who are Marker Therapeutics' key executives?

Marker Therapeutics' management team includes the following people:
  • Mr. Peter L. Hoang MBA, Pres, CEO & Director (Age 48, Pay $451.67k)
  • Mr. Anthony H. Kim, Chief Financial Officer (Age 44, Pay $431.52k)
  • Dr. Juan F. Vera M.D., Chief Devel. Officer & Director (Age 40)
  • Dr. Mythili Koneru M.D., Ph.D., Chief Medical Officer (Age 42, Pay $405.11k)
  • Mr. Michael J. Loiacono, Chief Accounting Officer, Treasurer & Sec. (Age 54)
  • Ms. Elizabeth Donnelly, Director of Admin.
  • Ms. Shelia Sterr, Director of HR & Fin.
  • Dr. Robert Z. Florkiewicz Sr., Sr. Director of Molecular Biology & Virology

What is Marker Therapeutics' stock symbol?

Marker Therapeutics trades on the NASDAQ under the ticker symbol "MRKR."

Who are Marker Therapeutics' major shareholders?

Marker Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vigilare Wealth Management (0.30%).
View institutional ownership trends for Marker Therapeutics
.

Which major investors are buying Marker Therapeutics stock?

MRKR stock was bought by a variety of institutional investors in the last quarter, including Vigilare Wealth Management.
View insider buying and selling activity for Marker Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Marker Therapeutics?

Shares of MRKR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Marker Therapeutics' stock price today?

One share of MRKR stock can currently be purchased for approximately $2.07.

How big of a company is Marker Therapeutics?

Marker Therapeutics has a market capitalization of $99.41 million and generates $210,000.00 in revenue each year. The company earns $-21,430,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis. Marker Therapeutics employs 28 workers across the globe.

What is Marker Therapeutics' official website?

The official website for Marker Therapeutics is www.markertherapeutics.com.

How can I contact Marker Therapeutics?

Marker Therapeutics' mailing address is 3200 Southwest Freeway Suite 2240, Houston TX, 77027. The company can be reached via phone at 713-400-6400 or via email at [email protected]

This page was last updated on 1/16/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.